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Objective: To validate a new method to identify responders (relative effect per patient (REPP) >0.2) using
the OMERACT-OARSI criteria as gold standard in a large multicentre sample.
Method: The REPP ([score before e after treatment]/score before treatment) was calculated for 845
patients of a large multicenter European cohort study for THR. The patients with a REPP >0.2 were
deﬁned as responders. The responder rate was compared to the gold standard (OMERACT-OARSI criteria)
using receiver operator characteristic (ROC) curve analysis for sensitivity, speciﬁcity and percentage of
appropriately classiﬁed patients.
Results: With the criterion REPP>0.2 85.4% of the patients were classiﬁed as responders, applying the
OARSI-OMERACT criteria 85.7%. The new method had 98.8% sensitivity, 94.2% speciﬁcity and 98.1% of the
patients were correctly classiﬁed compared to the gold standard.
Conclusion: The external validation showed a high sensitivity and also speciﬁcity of a new criterion to
identify a responder compared to the gold standard method. It is simple and has no uncertainties due to
a single classiﬁcation criterion.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Total hip replacement (THR) is one of the most successful
treatment procedures for patients with hip osteoarthritis; THR al-
leviates the symptoms (e.g., pain and stiffness) and degree of dis-
ability1e4. The success of THR can be measured as responder rate
deﬁned by Outcome Measures in Rheumatoid Arthritis Clinical
Trials/Osteoarthritis Research Society International (OMERACT-
OARSI) with patient reported outcome measurement tools
(PROM's)5e11. The responder rate for a surgical treatment (e.g., THR)J. Huber, Department of Or-
7, Postfach, CH 8063 Zurich,
2-43.
. Huber).
r Ltd and Osteoarthritis Research Scontains valuable information and is easy to understand either for
patients and general practitioners, surgeons and medical care
providers12e14. For example in the multicenter EUROHIP study the
responder rate for THR was 85.4%, meaning that 6 out of 7 patients
had a clinical improvement above the level of a minimally clinically
important difference and one of 7 patients does not proﬁt from THR
(being a “non-responder”)12. This information may be helpful
either for decision making for the patients and for process
amelioration for surgeons analyzing possible factors to become a
responder or possible factors to become a “non-responder”.
But the method to calculate the responder rate is complex
because one main criterion or two out of three subcriterias
regarding pain or function needed to be fulﬁlled5. An easier method
simple to calculate would be helpful to overcome this limitation. In
the validation study of the relative effect per patient (REPP) [Fig. 1]ociety International. This is an open access article under the CC BY-NC-ND license
REPP =   (pre-treatment score) minus (post-treatment score)
(pre-treatment score)
Example 1: pre-treatment score 48, post-treatment score 2; 
REPP = 48-2/48 = 46/48 = 0.96 = responder
Example 2: pre-treatment score 25, post-treatment score 16;
REPP = 25-16/25 = 9/25 = 0.36 = responder
Example 3: pre-treatment score 13, post-treatment score 35; 
REPP = 13-35/13 = -22/35 = -0.63 = non-responder
Fig. 1. REPP formula and calculating REPP scores: three examples.
Fig. 2. Venn-diagram to show overleap between REPP score and OARSI-OMERACT
responder criteria.
J. Huber et al. / Osteoarthritis and Cartilage 24 (2016) 480e483 481the threshold was deﬁned with 0.2, representing a change equal or
larger than the minimal clinically important difference (MCID)15.
Incidentally a high agreement was found between the patients with
a REPP>0.2 (91%) and the responder rate using the set of OMERACT-
OARSI criteria (92%)15.
The aim of this study was to validate this ﬁnding externally in a
highly generalizable sample of patients undergoing THR for pri-
mary OA in 12 European nations and to determine whether it
identiﬁes the same patients as responders using the OMERACT-
OARSI method as the gold standard.
Method
We included patients who were enrolled in the EUROHIP study
and had complete PROMs from the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) follow-ups pre-THR
and one year postoperatively for the patients with unilateral
THR4,12. The EUROHIP study included 1327 patients who under-
went primary THR at 20 European orthopedic centers in 12 nations.
The study began by collecting data in January 2004 and concluded
in December 2006. The inclusion criteria were having a diagnosis of
hip OA, undergoing primary THR, and providing signed informed
consent. The exclusion criteria were severe mental illness or de-
mentia and patients who were unwilling/unable to participate.
Each center was responsible for obtaining local ethical approval.
The study protocol and data collection forms were designed in
Bristol, UK and Ulm, Germany by the study principle investigators
(Paul Dieppe, Klaus-Peter Günther and Karsten Dreinh€ofer). The
patient questionnaire was reviewed for acceptability in Bristol and
modiﬁed accordingly before it was sent to Ulm for translation and
distribution. Questionnaires were sent to each center for trans-
lation and were returned for editing before being printed and
distributed with a set of instructions.
The WOMAC score was calculated including all 24 questions of
three dimensions pain, stiffness and physical function on a scale
0 indicating no symptoms and 100 extreme symptoms.
Outcome
We deﬁned the patient outcome using the responder rate
calculated with the REPP score (REPP>0.2) as new criterion and
compared it to the rate using the OMERACT-OARSI criteria as gold
standard.
REPP score and responder criterion
The REPP (pre treatment (tt) score e post tt score)/pre tt score)
was calculated for each patient with the WOMAC score [Fig. 1].
Every patient with a REPP >0.2 was deﬁned as responder15.
OMERACT-OARSI responder criteria
The OMERACT-OARSI responder criteria (Pham et al.) indicate
a substantial improvement in pain or function of 50% and anabsolute change of 20. If the patient does not fulﬁll these
criteria, improvement in 2 of the three following criteria is
necessary: 20% improvement in pain and an absolute change of
10, 20% improvement in function and an absolute change of
10, 20% improvement in the patient's global assessment, and
an absolute change of 105.
Statistical analysis
Descriptive statistics were used to determine the score vari-
ability before and after THR, as well as the number of responders.
Cross tabulation of both methods was conducted to assess the
percentage of patients whowere appropriately classiﬁed. Receiver
operator characteristic (ROC) curve analysis was used to assess the
sensitivity, speciﬁcity, and percentage of patients who were
appropriately classiﬁed compared to the newly proposed method,
using the OARSI as the gold standard. Stata 13.1 software (Stata
Corp., College Station, TX, USA) was used for all statistical
analyses.
Results
All patients with complete outcome data from the preoperative
and 12-month postoperative assessments (n ¼ 845, comprising
63.7% of all included patients) were included. The average patient
age was 65.7 years (range, 26e92 years).
The median WOMAC score of the patients before and after
THR decreased from 58.3 to 15.6 (P < 0.001). The REPP-scores
ranged from 1 to 1.5, peaking at approximately 1 and slowly
decreasing to zero; there were few results near or below zero, as
well as an outlier. For the EUROHIP cohort, the relative pro-
portions of responders were 85.4% and 14.6% non-responders
(12.7% unchanged, and 1.9% worse). Using the OARSI-OMERACT
criteria, we identiﬁed 85.7% of the patients as responders.
Both methods classiﬁed nearly the same patients as responders
with 98.8% sensitivity, 94.2% speciﬁcity and 98.1% correctly classi-
ﬁed, demonstrating good validation of the new REPP method to
calculate the responders [Fig. 2].
Discussion
Main ﬁndings
The criterion REPP>0.2 to deﬁne a responder correlates with
high sensitivity and also high speciﬁty with the existing set of
OARSI-OMERACT criteria. The responder rate can be calculated
simple and easier with REPP method.
J. Huber et al. / Osteoarthritis and Cartilage 24 (2016) 480e483482Strengths/limitations
The strength of this study is the large number of participating
patients in 12 nations with PROM's in 10 different languages at 20
centers allowing a reliable external validation of this new method.
Study limitations were the selection bias of patients and
treatment.
The included patients (unilateral osteoarthritis of the hip, un-
dergoing THR) were similar to those in the validation study.
A basic bias of the EUROHIP study group was that all partici-
pating surgeons and centers had a special interest in THR and in
clinical science; therefore, the analyzed cohort may represent a
positive patient selection and the responder rate may be higher
than in general practice.
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